Posts by: Patricia Inacio PhD

Patricia Inacio PhD

June 8, 2018

Immunotherapy Targeting Tumor Mutations Leads to Complete Response in Advanced Breast Cancer Patient, NIH Reports

News

A tweaked version of a cellular immunotherapy that recognizes mutations in a patient’s tumor has led to the complete regression of metastatic breast cancer in a woman whose disease had ... Read more

May 4, 2018

Advanced Melanoma Patients Seen to Respond to CMP-001, Keytruda Combo in Ongoing Study

News

Intratumoral injection of CMP-001 in combination with Keytruda (pembrolizumab) worked to reduce tumor burden in advanced melanoma patients whose disease failed to respond, or progressed, when treated with PD-1 inhibitors, data ... Read more

April 24, 2018April 24, 2018

CAR T-cell Therapy at Higher Dose Might Treat Advanced Neuroblastoma, Early Trial Results Suggest

News

At higher doses, an immunotherapy approach using chimeric antigen receptor (CAR) T-cells may help to treat advanced neuroblastoma, a rare cancer that mostly affects babies and young children, according to early ... Read more

April 6, 2018April 6, 2018

Five Prime Doses First Patient With Investigational Antibody FPA150

News

The Phase 1 clinical trial testing FPA150, an investigational antibody targeting the B7-H4 protein, in patients with solid tumors has dosed its first participant, Five Prime Therapeutics announced. Patients eligible for the ... Read more

April 3, 2018April 3, 2018

New Technology that Takes ‘Instagram’ of Immune System May Open Door for Precision Cancer Therapies

News

A new technology that creates a sort of “Instagram” of the immune system may help predict a patient’s response to cancer immunotherapies, researchers say. “What I use here is a ... Read more

March 12, 2018March 12, 2018

Phase 3 Trial of Idera’s IMO-2125 Combo Therapy Is Recruiting Advanced Melanoma Patients

News

A new Phase 3 trial for advanced melanoma patients who failed to respond to Opdivo (nivolumab) or Keytruda (pembrolizumab) is recruiting participants to evaluate Idera Pharmaceutical‘s experimental immunotherapy, IMO-2125, in combination with ... Read more

March 8, 2018March 8, 2018

New Dosing Schedule Allows Patients to Receive Opdivo Every Four Weeks

News

The U.S. Food and Drug Administration (FDA) has approved a new dosing schedule for Opdivo (nivolumab), allowing the medicine to be offered every four weeks in addition to the previously available ... Read more

February 27, 2018February 27, 2018

Re-engineered Cold Virus Increases Brain Cancer Patients’ Survival, Phase 1 Trial Shows

News

Re-engineering a common cold virus to attack the deadliest kind of brain tumor extended the survival of patients whose tumor returned after various treatments, including surgery, a Phase 1 clinical ... Read more

February 21, 2018February 21, 2018

Imfinzi Is First Immunotherapy Approved for Advanced Non-small Cell Lung Cancer in US

News

Imfizi (durvalumab) has become the first approved immunotherapy in the United States for patients with advanced non-small cell lung cancer that has stabilized. The U.S. Food and Drug Admnistration authorization applies ... Read more

February 20, 2018February 20, 2018

Imfinzi Seen to Safely Help Certain Patients with Advanced Head and Neck Cancer in Phase 2 Trial

News

Data from the Phase 2 CONDOR trial continue to support the safety, and show some efficacy, of treatment with Imfinzi (durvalumab) in certain pre-treated patients with advanced head and neck cancer. ... Read more